Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes

In Practice Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00803660

Enrollment

1060

Registered

2008-12-05

Start date

2008-11-30

Completion date

2009-05-31

Last updated

2009-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Type 2 Diabetes

Keywords

hypertension, BP, diabetes, anti-hypertensive treatment, ACE-I, ARB

Brief summary

Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP\<130/80 mmHg. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP\<130/80 mmHg by treatment groups. To observe the proportion of patients achieving a therapeutic glycemic response defined as HbA1c=\<7%. To observe the proportion of patients achieving fasting plasma glucose\<110 mg%. To identify factors for not achieving BP\<130/80 mmHg. To describe percentage of patients with positive proteinuria (including microalbuminuria) by treatment groups .

Interventions

None listed

Study design

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Provision of written informed consent * Patient was diagnosed with type 2 diabetes * Patient is on antihypertensive treatments for at least 3 months, with the same regimen for a minimum of 4 weeks prior to survey

Exclusion criteria

* Patients are critically ill, had mental health problems or difficulty in communication * Patients who are unwilling or unable to provide informed consent * Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).

Design outcomes

Primary

Measure	Time frame
The number of patients achieving the BP<130/80 mmHg	—
The percentage of patients achieving the BP<130/80 mmHg	—

Secondary

Measure	Time frame
The number and percentage of patients achieving the FPG<110 mg%	—
The number and percentage of patients achieving the BP<130/80 mmHg by treatment groups	—
The number and percentage of patients with positive proteinuria by treatment groups	—
The association between unachievement of BP<130/80 mmHg and other factors (age, gender, CV risk factors, CV and diabetes history, duration of type of treatment...)	—
The number and percentage of patients achieving HbA1c=<7%	—

Countries

Vietnam

Outcome results